(Total Views: 295)
Posted On: 05/19/2022 3:21:31 AM
Post# of 1418
Some post incessantly and still have zero clue what the company does.
Telling Gerald he , must , needs to , should have and have all kinds of opinions from there armchair and don't even understand the basics of Todos Medical.
They are not working on a breast cancer drug.
It's a breast cancer diagnostic.
It's called Videssa and it's at commercial stage now and is a test that Provista Diagnostics lab will screen for.
https://www.provistadx.com/videssa-breast-cancer-blood-test
They also have TBIA platform which also tests for cancers, which they will piggyback on Videssa to speed up the trials.
https://todosmedical.com/rd-pipeline?hsLang=en
Todos’ proprietary TBIA platform will be able to piggyback on the sample volume we anticipate generating from Videssa in order to further refine its algorithms and begin deploying our proprietary TBIA immunosurveillance blood testing assay for breast cancer, colon cancer and other cancers,” continued Dr. Leon. “We believe this strategy will allow us to dramatically accelerate the timeline of bringing TBIA into the market in the United States and allow us to scale that platform more rapidly.”
https://www.globenewswire.com/news-release/20...-Test.html
Telling Gerald he , must , needs to , should have and have all kinds of opinions from there armchair and don't even understand the basics of Todos Medical.
They are not working on a breast cancer drug.
It's a breast cancer diagnostic.
It's called Videssa and it's at commercial stage now and is a test that Provista Diagnostics lab will screen for.
https://www.provistadx.com/videssa-breast-cancer-blood-test
They also have TBIA platform which also tests for cancers, which they will piggyback on Videssa to speed up the trials.
https://todosmedical.com/rd-pipeline?hsLang=en
Todos’ proprietary TBIA platform will be able to piggyback on the sample volume we anticipate generating from Videssa in order to further refine its algorithms and begin deploying our proprietary TBIA immunosurveillance blood testing assay for breast cancer, colon cancer and other cancers,” continued Dr. Leon. “We believe this strategy will allow us to dramatically accelerate the timeline of bringing TBIA into the market in the United States and allow us to scale that platform more rapidly.”
https://www.globenewswire.com/news-release/20...-Test.html
(1)
(0)
